CompletedNCT04827056

Dexmedetomidine (DEX) for sublingual (SL) administration - 40µg for PTSD

This study is completed in the United States. It is testing Dexmedetomidine (DEX) for sublingual (SL) administration - 40µg for PTSD.

PTSD, Addiction, ...DrugFrom 21 Years to 65 Years

The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.

Explore recruiting studies on this topic

Then choose your country and confirm availability with each study site.

The study in practice

Understand this study

Who could participate?

Listed age limits: 21 years to 65 years.

Listed locations: West Haven, United StatesSee all locations and recruitmentA listed location does not confirm current availability.

Compensation and expense reimbursement have not been verified for this summary.

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: November 9, 2021

Recruitment status: Completed
Enrollment listed in the registry: 10
Sponsor: Pharmacotherapies for Alcohol and Substance Use Disorders Alliance
Sponsor type: Unknown or unclear
Study type: Drug
Intervention type: Psychotherapy / behavioral intervention, Medication / drug, PROCEDURE
Study phase: Phase 1
Locations: United States
Age range: From 21 Years to 65 Years
Official registry ID: NCT04827056
Official title: Effect of Sublingual Formulation of Dexmedetomidine HCl (BXCL501) on Ethanol in Heavy Drinkers With PTSD - Alcohol Interaction Study

Ask HopeStage to help me review this study

This record does not confirm open recruitment. We can help you understand it and explore other studies.

Study ID: NCT04827056. We help you review the study, but cannot decide medical eligibility.

Recruitment & locations

Completed

West Haven

FAQ

Questions about this study

Who is behind this study?

The study sponsor is Pharmacotherapies for Alcohol and Substance Use Disorders Alliance.

Does this study involve medication?

Yes. The study involves medication, including Placebo, Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg and Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 80µg.

Who can participate?

Listed age limits: 21 years to 65 years.

Is this study still recruiting?

The registry lists this study as completed.

Explore other studies

Want to find a study that may fit you better?

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.

Find a study that may fit me